معرفی
Lars Henning Engelholm is a Professor in the Department of Biomedical Sciences at the University of Copenhagen's Faculty of Health and Medical Sciences. With 72 research outputs including 65 journal articles, 6 reviews, and 1 conference abstract, he maintains an active research program focused on cancer therapeutics and molecular biology. His work bridges basic science with clinical applications through innovative drug delivery approaches.
Dr. Engelholm's research focuses on cancer therapeutics with particular emphasis on antibody-drug conjugates (ADCs), bioconjugation techniques, and targeted therapy development. His work spans multiple cancer types including breast cancer, pancreatic cancer, ovarian cancer, and malignant pleural mesothelioma. He has made significant contributions to understanding drug delivery mechanisms, tumor microenvironment interactions, and novel payload development for cancer treatment.
His recent publications demonstrate a strong trend toward developing next-generation antibody-drug conjugates with improved targeting capabilities and novel payload systems. Research areas include bioconjugation chemistry, cancer stem cell targeting, immune microenvironment modulation, and organoid-based drug response profiling. His 2024 review in Cancers journal has received 40 Scopus citations, indicating significant impact in the field.
- Cited 40 times in Scopus for 2024 Cancers review article
- Patent Family Citation for Science Advances pancreatic cancer research
- Multiple news outlets have covered his research (6 outlets for the HER2 nanobody-drug conjugate work)
- Research referenced in patents and widely shared on social media platforms
Dr. Engelholm maintains extensive collaborations across multiple institutions, with research picked up by numerous news outlets, blogged about, and widely shared on social media platforms including X (formerly Twitter) and Bluesky. His work demonstrates strong translational potential with several studies moving toward preclinical and clinical applications.
